Related references
Note: Only part of the references are listed.Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
Yanli Sun et al.
FRONTIERS IN PHARMACOLOGY (2021)
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE
Andrew D. J. Pearson et al.
EUROPEAN JOURNAL OF CANCER (2021)
Achieving clinical success with BET inhibitors as anti-cancer agents
Tatiana Shorstova et al.
BRITISH JOURNAL OF CANCER (2021)
4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity
Huarui Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression
Katherine L. Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Paradigm shift: combination BET and JAK inhibition in myelofibrosis
John Mascarenhas et al.
LEUKEMIA (2021)
Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
Shipeng He et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
Emily J. Faivre et al.
NATURE (2020)
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Omer Gilan et al.
SCIENCE (2020)
Characterization of a dualBET/HDACinhibitor for treatment of pancreatic ductal adenocarcinoma
Xin Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins
Robert J. Watson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity
Ellen Watts et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Bromodomains: a new target class for drug development
Andrea G. Cochran et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
Bing Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
Chong Qin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth
Chunyan Ren et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
Hatice Gulcin Ozer et al.
CANCER DISCOVERY (2018)
Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains
Jinhua Wang et al.
ACS CHEMICAL BIOLOGY (2018)
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
Amanda Balboni Iniguez et al.
CANCER CELL (2018)
Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor
Jianping Hu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxylethy]-1,3-dimethyl-piperazin-2-one (AZD5153)
Robert H. Bradbury et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design and characterization of bivalent BET inhibitors
Minoru Tanaka et al.
NATURE CHEMICAL BIOLOGY (2016)
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Anastasios Stathis et al.
CANCER DISCOVERY (2016)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim et al.
LANCET HAEMATOLOGY (2016)
Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia
Sarah Picaud et al.
SCIENCE ADVANCES (2016)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization
Lele Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
Pawel K. Mazur et al.
NATURE MEDICINE (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536
Lijia Chen et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
Stuart W. J. Ember et al.
ACS CHEMICAL BIOLOGY (2014)
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Pietro Ciceri et al.
NATURE CHEMICAL BIOLOGY (2014)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
Lewis R. Vidler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Sarah Picaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors
Victor S. Gehling et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Panagis Filippakopoulos et al.
CELL (2012)
Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
Lewis R. Vidler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription
MK Jang et al.
MOLECULAR CELL (2005)
Selective small molecules blocking HIV-1 Tat and coactivator PCAF association
L Zeng et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2005)
Share Paper
